Accelerate to discover

Back to filter

Related topics

EV's and Nanoparticles in "Full Spectrum View" with the new Cytek ESP module

Cytek Biosciences

Jul 19, 2024

Cytek’s Enhanced Small Particle (ESP) Detection Option expands the capability of your Cytek Aurora or Cytek Northern...

Automatic, Real Time Acquisition of Bioluminescent Kinetic Curves

Spectral Instruments Imaging

Jun 27, 2024

Watch this pre-recorded webinar with Dr. Andrew Van Praagh to learn how our new Aura software feature —Kinetics—...

Theranostics: From Mice to Men and Back

MOLECUBES

Jun 25, 2024

Recorded webinar
Presenters: Prof. Dr. Ken Herrmann and Prof. Dr. Katharina Lückerath – Moderator: Hannah Notebaert

Orion 2024 AACR poster: 17-plex single-step stain and imaging of cell Lung Carcinoma

RareCyte

Jun 21, 2024

RareCyte Orion is a benchtop, high resolution, whole slide multimodal imaging instrument. A combination of quantitative...

Jul 22, 2024

New release now available: Cytek Amnis AI v3.0 Software

Cytek Biosciences

Jun 17, 2024

The new Cytek Amnis AI v3.0 image analysis software features an integrated transfer learning algorithm, an option to...

Cytek webinar: Imaging Flow Cytometry for Chromosomal Assessment in Hematological Malignancies

Cytek Biosciences

Jun 7, 2024

In this webinar, we will describe a new innovative approach we developed that resolves these limitations. The method...

Hypoxia in the Tumor Immune Microenvironment (TIME)

Bruker Biospin

Jun 6, 2024

Thursday, 11 July 2024, 16:00 CET | 10:00 EST
Zaver M. Bhujwalla, PhD...

Jul 22, 2024

X-RAD 320 for irradiation therapy during quantifying study for in vivo collagen reorganization

Precision X-Ray

Jun 5, 2024

Quantifying in vivo collagen reorganization during immunotherapy in murine melanoma with second harmonic generation...

Show all topics (10)

Preclinical cardiac safety assesment

Mar 22, 2016

Over the last two decades, a number of blockbuster drugs have been withdrawn or have incurred safety warnings by regulatory agencies due to adverse cardiac effects. In addition, lead compounds or drug candidates are frequently terminated at late stages of drug development due to cardiac safety concerns. Both of these factors can significantly impact the overall cost of drug discovery; consequently, pharmaceutical companies and regulatory agencies have implemented procedures to address these issues.

Most, if not all, in vitro assay systems for cardiac safety are designed to screen for surrogates of arrhythmia, such as hERG channel interaction, rather than arrhythmia itself. Assays designed to screen for compounds that may affect repolarization and induce arrhythmia in the context of the whole heart or heart tissue are not implemented until much later in drug development. These include sophisticated, technically demanding, lowthroughput, and costly procedures such as the Purkinje fiber assay, ventricular wedge assay, and the Langendorff whole heart assay, or telemetry experiments in live and anesthetized animals. The field of preclinical cardiac safety can certainly benefit from an assay system that allows for integrated assessment of compound action on ion channel and non-ion channel targets involved in cardiac excitation-contraction coupling.

The RTCA Cardio Instrument in conjunction with iCell Cardiomyocytes comprises an assay system providing integrated assessment of compound action on multiple targets involved in heart function. This assay system can sensitively and quantitatively detect the effect of compounds on the major ion channels involved in heart function, namely calcium, sodium, and potassium channels. Another major advantage of the assay system is the time resolution. The RTCA Cardio Instrument has a data acquisition rate of 12.5 ms per well of a 96-well plate and can be used simultaneously to monitor acute and chronic drug effects up to days and weeks. The utility of the time-dependent monitoring of compound action on cardiomyocytes can be demonstrated by testing compounds that acutely and directly block hERG channels (E4031, cisapride, etc.) and compounds that interfere with protein trafficking (pentamidine) in a sub-chronic manner. The RTCA Cardio Instrument is able to detect the effects of these compounds on the beating rate and duration of iCell Cardiomyocytes.

The xCELLigence System RTCA Cardio Instrument, in conjunction with iCell Cardiomyocytes, represents a physiologically relevant and predictive assay system for preclinical cardio-safety assessment of lead compounds. The features of this assay system, including time resolution, dynamic monitoring of mechanical beating activity of cardiomyocytes, and 96-well throughput, will surely provide additional mechanistic and toxicity information for compound action on the heart.

Application
Product news

Related technologies: Real-time, label free cell analysis

Brand profile

Agilent technologies

Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

Cardio Instrument is a high-resolution system for label-free-dual-mode monitoring of cardiomyocyte and cardiotoxicity testing

show detail

The new CardioECR system combines impedance and Multi Electrode Array (MEA) technology with a pacing function

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey